Informace o publikaci

Colchicine for prevention of vascular inflammation in Non-CardioEmbolic stroke (CONVINCE) - study protocol for a randomised controlled trial

Autoři	KELLY P. WEIMAR C. LEMMENS R. MURPHY S. PURROY F. ARSOVSKA A. BORNSTEIN N. M. CZLONKOWSKA A. FISCHER U. FONSECA A. C. FORBES J. HILL M. D. JATUZIS D. KORV J. KRUUSE C. MIKULÍK Robert NEDERKOORN P. J. O DONNELL M. SANDERCOCK P. TANNE D. TSIVGOULIS G. WALSH C. WILLIAMS D. ZEDDE M. PRICE C. I.
Rok publikování	2021
Druh	Článek v odborném periodiku
Časopis / Zdroj	EUROPEAN STROKE JOURNAL
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
www	https://journals.sagepub.com/doi/10.1177/2396987320972566
Doi	http://dx.doi.org/10.1177/2396987320972566
Klíčová slova	Ischaemic stroke; inflammation; colchicine; randomised controlled trial
Popis	Background: Inflammation contributes to unstable atherosclerotic plaque and stroke. In randomised trials in patients with coronary disease, canukinumab (an interleukin-1B antagonist) and colchicine (a tubulin inhibitor with pleiotropic anti-inflammatory effects) reduced recurrent vascular events. Hypothesis: Anti-inflammatory therapy with low-dose colchicine plus usual care will reduce recurrent vascular events in patients with non-severe, non-cardioembolic stroke and TIA compared with usual care alone. Design: CONVINCE is a multi-centre international (in 17 countries) Prospective, Randomised Open-label, Blinded-Endpoint assessment (PROBE) controlled Phase 3 clinical trial in 3154 participants. The intervention is colchicine 0.5 mg/day and usual care versus usual care alone (antiplatelet, lipid-lowering, antihypertensive treatment, lifestyle advice). Included patients are at least 40 years, with non-severe ischaemic stroke (modified Rankin score <= 3) or high-risk TIA (ABCD2> 3, or positive DWI, or cranio-cervical artery stenosis) within 72 hours-28 days of randomisation, with qualifying stroke/TIA most likely caused by large artery stenosis, lacunar disease, or cryptogenic embolism. Exclusions are stroke/TIA caused by cardio-embolism or other defined cause (e.g. dissection), contra-indication to colchicine (including potential drug interactions), or incapacity for participation in a clinical trial. The anticipated median followup will be 36months. The primary analysis will be by intention-to-treat. Outcome: The primary outcome is time to first recurrent ischaemic stroke, myocardial infarction, cardiac arrest, or hospitalisation with unstable angina (non-fatal or fatal). Summary: CONVINCE will provide high-quality randomised data on the efficacy and safety of anti-inflammatory therapy with colchicine for secondary prevention after stroke. Schedule: First-patient first-visit was December 2016. Recruitment to complete in 2021, follow-up to complete in 2023.